David W.  Gryska net worth and biography

David Gryska Biography and Net Worth

Director of Seagen
Mr. David W. Gryska is an Independent Director of Seattle Genetics, Inc., since March 2005. From October 2014 through December 2018, Mr. Gryska served as Executive Vice President and Chief Financial Officer of Incyte Corporationrationration, a publiclytraded biopharmaceutical company. From May 2012 to December 2012, Mr. Gryska served as Chief Operating Officer and from August 2012 to December 2012, interim Chief Executive Officer of Myrexis Inc., a publiclytraded biotechnology company. From December 2006 to October 2010, he served as Senior Vice President and Chief Financial Officer of Celgene Corporationrationration. From October 2004 to December 2006, he was a principal at Strategic Consulting Group, where he provided strategic consulting to earlystage biotechnology companies. Mr. Gryska served at Scios, Inc., a biopharmaceutical company, as Senior Vice President and Chief Financial Officer from November 2000 to October 2004, and as Vice President of Finance and Chief Financial Officer from December 1998 to November 2000. Scios was acquired by Johnson Johnson in 2003. From 1993 to December 1998, he served as Vice President, Finance and Chief Financial Officer at Cardiac Pathways Corporationrationration, a medical device company which was later acquired by Boston Scientific Corporationrationration. Prior to Cardiac Pathways, Mr. Gryska served as a partner at Ernst Young LLP, an accounting firm. During his eleven years at Ernst Young LLP, he focused on technology industries, with an emphasis on biotechnology and healthcare companies.

Gryska holds a B.A. in accounting and finance from Loyola University and an M.B.A. from Golden Gate University. In addition to Seattle Genetics, Mr. Gryska serves on the board of PDL BioPharma, Inc. and Aerie Pharmaceuticals, Inc., both publiclytraded biotechnology companies. With his years of experience as Chief Financial Officer, at Incyte Corporationrationrationration, Celgene, Scios, and Cardiac Pathways.

What is David W. Gryska's net worth?

The estimated net worth of David W. Gryska is at least $9.21 million as of November 11th, 2022. Mr. Gryska owns 40,253 shares of Seagen stock worth more than $9,207,471 as of March 28th. This net worth evaluation does not reflect any other investments that Mr. Gryska may own. Learn More about David W. Gryska's net worth.

How do I contact David W. Gryska?

The corporate mailing address for Mr. Gryska and other Seagen executives is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. Seagen can also be reached via phone at (425) 527-4000 and via email at [email protected]. Learn More on David W. Gryska's contact information.

Has David W. Gryska been buying or selling shares of Seagen?

David W. Gryska has not been actively trading shares of Seagen over the course of the past ninety days. Most recently, David W. Gryska sold 7,500 shares of the business's stock in a transaction on Friday, November 11th. The shares were sold at an average price of $129.10, for a transaction totalling $968,250.00. Following the completion of the sale, the director now directly owns 40,253 shares of the company's stock, valued at $5,196,662.30. Learn More on David W. Gryska's trading history.

Who are Seagen's active insiders?

Seagen's insider roster includes Roger Dansey (Insider), David Epstein (CEO), David Gryska (Director), Vaughn Himes (Insider), Marc Lippman (Director), Jean Liu (EVP), Charles Romp (EVP), Clay Siegall (CEO), Todd Simpson (CFO), and Daniel Welch (Director). Learn More on Seagen's active insiders.

Are insiders buying or selling shares of Seagen?

In the last twelve months, insiders at the biotechnology company sold shares 28 times. They sold a total of 162,022 shares worth more than $33,110,171.31. The most recent insider tranaction occured on November, 10th when CEO David R Epstein sold 10,620 shares worth more than $2,262,166.20. Insiders at Seagen own 25.9% of the company. Learn More about insider trades at Seagen.

Information on this page was last updated on 11/10/2023.

David W. Gryska Insider Trading History at Seagen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/11/2022Sell7,500$129.10$968,250.0040,253View SEC Filing Icon  
4/19/2022Sell4,000$143.95$575,800.0046,250View SEC Filing Icon  
2/7/2022Sell4,500$138.76$624,420.00View SEC Filing Icon  
1/28/2022Sell4,500$122.56$551,520.00View SEC Filing Icon  
1/14/2022Sell4,500$135.24$608,580.00View SEC Filing Icon  
11/19/2020Sell15,000$173.70$2,605,500.00View SEC Filing Icon  
11/5/2020Sell4,500$180.60$812,700.00View SEC Filing Icon  
10/1/2019Sell5,000$85.09$425,450.00View SEC Filing Icon  
7/17/2019Sell5,000$75.00$375,000.00View SEC Filing Icon  
4/1/2019Sell5,000$73.41$367,050.00View SEC Filing Icon  
1/8/2019Sell5,000$65.04$325,200.0050,050View SEC Filing Icon  
11/5/2015Sell10,000$43.57$435,700.0023,950View SEC Filing Icon  
9/3/2013Sell10,000$42.48$424,800.00View SEC Filing Icon  
2/25/2013Sell10,000$27.17$271,700.00View SEC Filing Icon  
See Full Table

David W. Gryska Buying and Selling Activity at Seagen

This chart shows David W Gryska's buying and selling at Seagen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Seagen Company Overview

Seagen logo
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.
Read More

Today's Range

Now: $228.74
Low: $228.74
High: $228.74

50 Day Range

MA: $228.74
Low: $228.74
High: $228.74

2 Week Range

Now: $228.74
Low: $123.77
High: $228.96

Volume

86 shs

Average Volume

1,478,439 shs

Market Capitalization

$42.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32